DexCom, Inc. (NASDAQ:DXCM) has been identified as one of the top 10 healthcare equipment stocks to buy according to hedge funds. Analyst William Plovanic from Canaccord Genuity recently adjusted the price target for DexCom, Inc. from $99 to $95 while maintaining a Buy rating on the stock. The company’s fourth-quarter results and 2026 outlook met expectations, with a continued focus on product refinements in the U.S. market to maintain its leadership in glucose sensors. The 15-day G7 product is expected to play a significant role this year, supporting margins in the long term. Internationally, DexCom, Inc. plans to offer tiered sensor solutions and enhance insurance coverage for CGM.
Baird analyst Jeff Johnson also reiterated an Outperform rating on DexCom, Inc. and raised the price target from $82 to $87, indicating a potential upside of almost 20%. Johnson’s revision followed the company’s fourth-quarter results, which presented no major surprises but highlighted favorable factors that prompted him to adjust his model.
DexCom, Inc. is a medical device company specializing in continuous glucose monitoring systems that help manage diabetes and metabolic conditions by monitoring glucose levels regularly. Some of its popular products include DexCom G6, DexCom G7, DexCom Share, DexCom Real-Time API, and DexCom ONE.
While DexCom, Inc. shows promise as an investment, there are other AI stocks with greater upside potential and lower downside risk. For investors seeking undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available.
In conclusion, DexCom, Inc. continues to make strides in the healthcare equipment industry with its innovative glucose monitoring systems. Analysts remain optimistic about the company’s growth prospects, making it a stock worth considering for investors.
